Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Shulamith Rizel"'
Autor:
Hadar Goldvaser, Omer Gal, Shulamith Rizel, Daniel Hendler, Victoria Neiman, Tzippy Shochat, Aaron Sulkes, Baruch Brenner, Rinat Yerushalmi
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background Smoking is associated with an increased incidence of hormone receptor positive breast cancer. Data regarding worse breast cancer outcome in smokers are accumulating. Current literature regarding the impact of smoking on breast can
Externí odkaz:
https://doaj.org/article/8dd94cf2e0bd42919afc47b33ec08365
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0162813 (2016)
OBJECTIVE:Perceptions of the role of oncology medical staff in supporting bereaved families have evolved with the transition to interdisciplinary cancer care. We investigated the interactions between oncology professionals and bereaved families. METH
Externí odkaz:
https://doaj.org/article/0eae6660bc7b412db79210b787c865ca
Autor:
Hadar Goldvaser, Shulamith Rizel, Daniel Hendler, Victoria Neiman, Daniel Shepshelovich, Tzippy Shochat, Aaron Sulkes, Baruch Brenner, Rinat Yerushalmi
Publikováno v:
International Journal of Endocrinology, Vol 2016 (2016)
Purpose. To evaluate the associations between metformin, insulin, statins, and levothyroxine and breast cancer characteristics and outcome. Methods. Retrospective chart review of patients treated in our institute for early estrogen receptor (ER) posi
Externí odkaz:
https://doaj.org/article/6c1bb93aef584d3cb6e9008b9026dfd9
Autor:
Rinat Yerushalmi, Hadar Goldvaser, Aaron Sulkes, Irit Ben-Aharon, Daniel Hendler, Victoria Neiman, Noa Beatrice Ciuraru, Luisa Bonilla, Limor Amit, Alona Zer, Tal Granot, Shulamith Rizel, Salomon M Stemmer
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e107273 (2014)
PURPOSE:Four cycles of docetaxel/cyclophosphamide (DC) resulted in superior survival than doxorubicin/cyclophosphamide in the treatment of early breast cancer. The original study reported a 5% incidence of febrile neutropenia (FN) recommending prophy
Externí odkaz:
https://doaj.org/article/24047b7a98b446a99673849962c523f7
Autor:
Yulia Kundel, Nicola J Nasser, Ofer Purim, Rinat Yerushalmi, Eyal Fenig, Raphael M Pfeffer, Salomon M Stemmer, Shulamith Rizel, Zvi Symon, Bella Kaufman, Aaron Sulkes, Baruch Brenner
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e68327 (2013)
Pain from bone metastases of breast cancer origin is treated with localized radiation. Modulating doses and schedules has shown little efficacy in improving results. Given the synergistic therapeutic effect reported for combined systemic chemotherapy
Externí odkaz:
https://doaj.org/article/1412513b190143dab8f7c54be817b51c
Autor:
Irit Ben-Aharon, Liat Vidal, Shulamith Rizel, Rinat Yerushalmi, Ofer Shpilberg, Aaron Sulkes, Salomon M Stemmer
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e70044 (2013)
The role of bisphosphonates (BP) in early breast cancer (BC) has been considered controversial. We performed a meta-analysis of all randomized controlled trials (RCTs) that appraised the effects of BP on survival in early BC.RCTs were identified by s
Externí odkaz:
https://doaj.org/article/7fbf8fdc196f4e78b59ec487c9e29d60
Autor:
Shulamith Rizel, Michelle Leviov, Debbie M Jakubowski, David B. Geffen, Ora Rosengarten, Mariana Steiner, Steven Shak, Avital Bareket-Samish, Noa Ben-Baruch, Margarita Tokar, Amit Itay, Daniela Katz, Julie Baron, Nicky Liebermann, Salomon M. Stemmer, Lior Soussan-Gutman, Beatrice Uziely, Bella Nisenbaum, Georgeta Fried
Publikováno v:
npj Breast Cancer, Vol 5, Iss 1, Pp 1-6 (2019)
NPJ Breast Cancer
NPJ Breast Cancer
The 21-gene Recurrence Score (RS) assay is a validated prognosticator/predictor of chemotherapy (CT) benefit in early-stage estrogen receptor (ER)-positive breast cancer (BC). Long-term data from real-life clinical practice where treatment was guided
Autor:
Ronit Abir, Rinat Yerushalmi, Shlomit Perry, Ana Tobar, Irit Ben-Aharon, Shulamith Rizel, Noa Hasky, Salomon M. Stemmer, Benny Fisch, Ruth Shalgi, Mattan Levi, Eran Sharon, David Margel
Publikováno v:
Oncotarget
// Irit Ben-Aharon 1, 5, * , Mattan Levi 2, * , David Margel 1, 5 , Rinat Yerushalmi 1, 5 , Shulamith Rizel 1 , Shlomit Perry 1, 5 , Eran Sharon 3, 5 , Noa Hasky 2 , Ronit Abir 4, 5 , Benny Fisch 4, 5 , Ana Tobar 6 , Ruth Shalgi 2 and Salomon Marcell
Autor:
Shulamith Rizel, S.M. Stemmer, Tamar Peretz, Ora Rosengarten, Larisa Ryvo, Nicky Liebermann, Georgeta Fried, Christer Svedman, Lior Soussan-Gutman, N Ben Baruch, Avital Bareket-Samish, Bella Nisenbaum, David B. Geffen, Debbie McCullough, Mariana Steiner
Publikováno v:
Cancer Research. 78:P1-07
Background: The 21-gene Recurrence Score (RS) Assay (Oncotype DX®) is a validated prognosticator and predictive of chemotherapy (CT) benefit in patients with hormone receptor (HR)+ human epidermal growth factor receptor 2 (HER2)-negative breast canc
Autor:
Steven Shak, Ora Rosengarten, Shulamith Rizel, Bella Nisenbaum, Christer Svedman, Noa Ben-Baruch, Mariana Steiner, Lior Soussan-Gutman, Salomon M. Stemmer, Georgeta Fried, Nicky Liebermann, David B. Geffen, Tamar Peretz, Debbie McCullough, Kevin Isaacs, Avital Bareket-Samish
Publikováno v:
npj Breast Cancer, Vol 3, Iss 1, Pp 1-7 (2017)
NPJ Breast Cancer
NPJ Breast Cancer
The Recurrence Score® is increasingly used in node-positive ER+ HER2-negative breast cancer. This retrospective analysis of a prospectively designed registry evaluated treatments/outcomes in node-positive breast cancer patients who were Recurrence S